Since the first reported case of the acquired immunodeficiency syndrome (AIDS) in 1981, an estimated 5-10 million persons worldwide have become infected with human immunodeficiency virus type 1 (HlV-l) or closely related retroviruses. Rational design of an effective vaccine to stem the spread of this infection is likely to require a thorough understanding of the host immune response to these viruses. Virus specific cytotoxic T lymphocytes have been shown to play a protective role in many of viral infections. As HIV is thought to be predominantly cell associated and can be transmitted directly from cell to cell, it is possible that the cell-mediated immune response plays a critical role as a host defense in this infection. We have previously reported an assay system which facilitates the detection of HlV-l specific cytotoxic T lymphocytes (CIL). The goal of this proposal is to examine the role of HIV-specific CTL at the clonal level. HIV-l specific CTL clones will be generated by limiting dilution, using as CD3-specific monoclonal antibody aa a stimulus to proliferation. Virus specific CTL clones generated in this manner will be used to a) examine the group vs. type specificity of the HIV-l specific CIL response, b) examine the role of major histocompatibility complex (MHC) antigens in restricting HIV specific cytotoxicity. c) identify immunogenic epitopes of the virus which elicit these responses and d) generate monoclonal anti-clonotypic antibodies. These studies should help to further define the role of the cellular immune response in HlV-l infection and may be directly relevant to vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028568-04
Application #
3143146
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1989-07-01
Project End
1994-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kiezun, Adam; Garimella, Kiran; Do, Ron et al. (2012) Exome sequencing and the genetic basis of complex traits. Nat Genet 44:623-30
McLaren, Paul J; Ripke, Stephan; Pelak, Kimberly et al. (2012) Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 21:4334-47
Pasaniuc, Bogdan; Rohland, Nadin; McLaren, Paul J et al. (2012) Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet 44:631-5
Brumme, Zabrina L; Li, Chun; Miura, Toshiyuki et al. (2011) Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 56:100-8
Brockman, Mark A; Brumme, Zabrina L; Brumme, Chanson J et al. (2010) Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 84:11937-49
Miura, Toshiyuki; Brumme, Zabrina L; Brockman, Mark A et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 84:7581-91
Julg, B; Williams, K L; Reddy, S et al. (2010) Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol 84:5540-9
International HIV Controllers Study (see original citation for additional authors) (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-7
Miura, Toshiyuki; Brockman, Mark A; Schneidewind, Arne et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 83:2743-55
Miura, Toshiyuki; Brumme, Chanson J; Brockman, Mark A et al. (2009) HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 83:3407-12

Showing the most recent 10 out of 75 publications